

Clifford A Hudis

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1026553/clifford-a-hudis-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

410
papers

39,277
citations

95
h-index

191
g-index

458
ext. papers

45,347
ext. citations

6.6
avg, IF

7.18
L-index

#	Paper	IF	Citations
410	CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101506	2.2	7
409	The Breast Cancer Weight Loss trial (Alliance A011401): A description and evidence for the lifestyle intervention.. <i>Obesity</i> , 2022 , 30, 28-38	8	0
408	Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance). <i>JNCI Cancer Spectrum</i> , 2021 , 5, pkab025	4.6	0
407	Retraction: Increased Levels of COX-2 and Prostaglandin E2 Contribute to Elevated Aromatase Expression in Inflamed Breast Tissue of Obese Women. <i>Cancer Discovery</i> , 2021 , 11, 1306	24.4	0
406	Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 443-452	9.7	8
405	First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 5178-5187	12.9	8
404	Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance). <i>Journal of Clinical Oncology</i> , 2020 , 38, 1284-1292	2.2	9
403	Reply to M. Hutton-Potts and A.M. Joshua. <i>JCO Oncology Practice</i> , 2020 , 16, 285-286	2.3	
402	Alterations in and promote clinical resistance to alpelisib plus aromatase inhibitors. <i>Nature Cancer</i> , 2020 , 1, 382-393	15.4	49
401	Discrepancies in Financial Self-Disclosures and Open Payments Reporting Among Authors of Clinical Oncology Research Studies. <i>Journal of Clinical Oncology</i> , 2020 , 38, 480-487	2.2	3
400	Personalized Management of Chemotherapy-Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance). <i>Journal of Clinical Pharmacology</i> , 2020 , 60, 444-452	2.9	4
399	Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4184-4193	2.2	28
398	Bridging the Gap Among Clinical Practice Guidelines for Pain Management in Cancer and Sickle Cell Disease. <i>JCO Oncology Practice</i> , 2020 , 16, e433-e442	2.3	0
397	Hydroxyapatite mineral enhances malignant potential in a tissue-engineered model of ductal carcinoma in situ (DCIS). <i>Biomaterials</i> , 2019 , 224, 119489	15.6	12
396	Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial). <i>Breast Cancer Research and Treatment</i> , 2019 , 176, 303-310	4.4	8
395	Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. <i>Journal of Clinical Oncology</i> , 2019 , 37, 423-438	2.2	218
394	Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1868-1875	2.2	120

393	Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2338-2348	2.2	25
392	Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up. <i>Oncologist</i> , 2019 , 24, e646-e652	5.7	3
391	CALGB (Alliance) 40603: Long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) and bevacizumab (Bev) in triple-negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 591-591	2.2	29
390	Copper-64 trastuzumab PET imaging: a reproducibility study. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2019 , 63, 191-198	1.4	12
389	Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Phase 2 Clinical Trial. <i>JAMA Network Open</i> , 2019 , 2, e1916211	10.4	5
388	Obesity-associated Breast Inflammation among Hispanic/Latina Breast Cancer Patients. <i>Cancer Prevention Research</i> , 2019 , 12, 21-30	3.2	8
387	The Impact of Obesity on Breast Cancer. <i>Current Oncology Reports</i> , 2018 , 20, 47	6.3	62
386	A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease. <i>Cancer Prevention Research</i> , 2018 , 11, 203-214	3.2	11
385	Characteristics and Prognostic Factors for Patients With HER2-overexpressing Breast Cancer and Brain Metastases in the Era of HER2-targeted Therapy: An Argument for Earlier Detection. <i>Clinical Breast Cancer</i> , 2018 , 18, 353-361	3	12
384	Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2018 , 18, 387-394	3	14
383	Monosomy 17 in potentially curable HER2-amplified breast cancer: prognostic and predictive impact. <i>Breast Cancer Research and Treatment</i> , 2018 , 167, 547-554	4.4	10
382	Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2018 , 24, 5292-5304	12.9	41
381	Breast carcinoma with 21-gene recurrence score lower than 18: rate of locoregional recurrence in a large series with clinical follow-up. <i>BMC Cancer</i> , 2018 , 18, 42	4.8	7
380	Longer follow-up on clinical outcomes of weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2 overexpressing metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e13005-e13005	2.2	13
379	Adiposity, Inflammation, and Breast Cancer Pathogenesis in Asian Women. <i>Cancer Prevention Research</i> , 2018 , 11, 227-236	3.2	24
378	Correlative imaging reveals physiochemical heterogeneity of microcalcifications in human breast carcinomas. <i>Journal of Structural Biology</i> , 2018 , 202, 25-34	3.4	23
377	The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. <i>Cancer Cell</i> , 2018 , 34, 427-438	2.6	339
376	Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study. <i>Breast Cancer Research and Treatment</i> , 2018 , 171, 325-334	4.4	2

375	Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative). <i>Journal of the American College of Surgeons</i> , 2017 , 224, 688-694	4.4	5
374	Assessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: An enhanced screening approach incorporating trabecular bone score. <i>Journal of Bone Oncology</i> , 2017 , 7, 32-37	4.5	16
373	Reply to L.B. Marks et al. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1258-1259	2.2	
372	Metabolic Obesity, Adipose Inflammation and Elevated Breast Aromatase in Women with Normal Body Mass Index. <i>Cancer Prevention Research</i> , 2017 , 10, 235-243	3.2	85
371	Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503). <i>Breast Cancer Research and Treatment</i> , 2017 , 163, 391-398	4.4	11
370	The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials. <i>European Journal of Cancer</i> , 2017 , 75, 245-258	7.5	66
369	Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience. <i>Oncologist</i> , 2017 , 22, 139-143	5.7	21
368	Menopause Is a Determinant of Breast Aromatase Expression and Its Associations With BMI, Inflammation, and Systemic Markers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 1692-1701	5.6	52
367	Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance). <i>AAPS Journal</i> , 2017 , 19, 1411-1423	3.7	6
366	Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 318, 197-198	27.4	895
365	The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis. <i>Breast Cancer Research and Treatment</i> , 2017 , 165, 65-76	4.4	18
364	MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR/HER2 Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 5218-5224	12.9	327
363	RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2017 , 17, 585-594.e4	3	25
362	Frailty and long-term mortality of older breast cancer patients: CALGB 369901 (Alliance). <i>Breast Cancer Research and Treatment</i> , 2017 , 164, 107-117	4.4	41
361	Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer. <i>Oncologist</i> , 2017 , 22, 642-647	5.7	24
360	Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527. <i>Journal of Clinical Oncology</i> , 2017 , 35, 421-431	2.2	49
359	Estimating the OncotypeDX score: validation of an inexpensive estimation tool. <i>Breast Cancer Research and Treatment</i> , 2017 , 161, 435-441	4.4	14
358	A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer. <i>Breast Cancer Research</i> , 2017 , 19, 89	8.3	32

357	Untapped Potential of Observational Research to Inform Clinical Decision Making: American Society of Clinical Oncology Research Statement. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1845-1854	2.2	62
356	Lymphedema, musculoskeletal events and arm function in older patients receiving adjuvant chemotherapy for breast cancer (Alliance A171302). <i>Breast Cancer Research and Treatment</i> , 2017 , 166, 793-808	4.4	6
355	Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design. <i>Npj Breast Cancer</i> , 2017 , 3, 37	7.8	54
354	Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017 , 166, 241-247	4.4	12
353	21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017 , 166, 69-76	4.4	22
352	Breast carcinoma with an Oncotype Dx recurrence score . <i>Cancer</i> , 2017 , 123, 131-137	6.4	14
351	Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update. <i>Annals of Surgical Oncology</i> , 2017 , 24, 38-51	3.1	64
350	Effects of Rapid Weight Loss on Systemic and Adipose Tissue Inflammation and Metabolism in Obese Postmenopausal Women. <i>Journal of the Endocrine Society</i> , 2017 , 1, 625-637	0.4	40
349	American Society of Clinical Oncology Summit on Addressing Obesity Through Multidisciplinary Provider Collaboration: Key Findings and Recommendations for Action. <i>Obesity</i> , 2017 , 25 Suppl 2, S34-S39	8	6
348	Abstract 4705: CTLA4 blockade with HER2-directed therapy (H) yields clinical benefit in women undergoing radiation therapy (RT) for HER2-positive (HER2+) breast cancer brain metastases (BCBM) 2017 ,		8
347	Seven-year (yr) follow-up of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 511-511	2.2	35
346	Overall survival results of a randomized trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment.. <i>Journal of Clinical Oncology</i> , 2017 , 35, LBA2-LBA2	2.2	4
345	Overall survival results of a randomized trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment.. <i>Journal of Clinical Oncology</i> , 2017 , 35, LBA2-LBA2	2.2	14
344	Docosahexaenoic Acid Supplementation is Not Anti-Inflammatory in Adipose Tissue of Healthy Obese Postmenopausal Women. <i>International Journal of Nutrition</i> , 2017 , 1, 31-49	2.2	4
343	ABC trial (A011502): A randomized phase III double blinded placebo controlled trial of aspirin as adjuvant therapy for node positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS586-TPS586 ^{2.2}		
342	Phase II study of gemcitabine (G), trastuzumab (H), and pertuzumab (P) for HER2-positive metastatic breast cancer (MBC) after prior pertuzumab-based therapy.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1037-1037	2.2	
341	Gonadotropin-Releasing Hormone Agonists for Ovarian Function Preservation in Premenopausal Women Undergoing Chemotherapy for Early-Stage Breast Cancer: A Systematic Review and Meta-analysis. <i>JAMA Oncology</i> , 2016 , 2, 65-73	13.4	104
340	Genome Sequencing of Multiple Primary Tumors Reveals a Novel PALB2 Variant. <i>Journal of Clinical Oncology</i> , 2016 , 34, e61-7	2.2	6

339	A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling. <i>Clinical Cancer Research</i> , 2016 , 22, 5729-5737	12.9	109
338	Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy. <i>Cancer Immunology Research</i> , 2016 , 4, 835-844	12.5	95
337	Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer. <i>Clinical Breast Cancer</i> , 2016 , 16, 487-493	3	4
336	Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update. <i>Practical Radiation Oncology</i> , 2016 , 6, e219-e234	2.8	92
335	Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4431-4442	2.2	105
334	Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance). <i>Breast Cancer Research and Treatment</i> , 2016 , 160, 297-304	4.4	42
333	Decreased gastrointestinal toxicity associated with a novel capecitabine schedule (7 days on and 7 days off): a systematic review. <i>Npj Breast Cancer</i> , 2016 , 2, 16006	7.8	8
332	Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. <i>New England Journal of Medicine</i> , 2016 , 375, 209-19	59.2	364
331	Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2925-34	2.2	384
330	Hepatic Resection or Ablation for Isolated Breast Cancer Liver Metastasis: A Case-control Study With Comparison to Medically Treated Patients. <i>Annals of Surgery</i> , 2016 , 264, 147-154	7.8	60
329	Response. <i>Journal of the National Cancer Institute</i> , 2016 , 108,	9.7	1
328	Noninvasive Detection of Inflammatory Changes in White Adipose Tissue by Label-Free Raman Spectroscopy. <i>Analytical Chemistry</i> , 2016 , 88, 2140-8	7.8	12
327	Obesity and Cancer Opportunities to Break the Link. <i>Current Breast Cancer Reports</i> , 2016 , 8, 22-31	0.8	4
326	Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2359-65	2.2	40
325	A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer. <i>Clinical Breast Cancer</i> , 2016 , 16, 87-94	3	1
324	Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1689-701	2.2	179
323	Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2016 , 34, 557-65	2.2	1084
322	Cardiac Surveillance Guidelines for Trastuzumab-Containing Therapy in Early-Stage Breast Cancer: Getting to the Heart of the Matter. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1030-3	2.2	60

321	The Genomic Landscape of Male Breast Cancers. <i>Clinical Cancer Research</i> , 2016 , 22, 4045-56	12.9	85
320	Systemic Correlates of White Adipose Tissue Inflammation in Early-Stage Breast Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 2283-9	12.9	124
319	Incidence of Adjacent Synchronous Invasive Carcinoma and/or Ductal Carcinoma In-situ in Patients with Lobular Neoplasia on Core Biopsy: Results from a Prospective Multi-Institutional Registry (TBCRC 020). <i>Annals of Surgical Oncology</i> , 2016 , 23, 722-8	3.1	63
318	Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. <i>JAMA Oncology</i> , 2016 , 2, 29-36	13.4	48
317	Biomarkers That Predict Sensitivity to Heat Shock Protein 90 Inhibitors. <i>Clinical Breast Cancer</i> , 2016 , 16, 276-83	3	9
316	Targeting obesity-related adipose tissue dysfunction to prevent cancer development and progression. <i>Seminars in Oncology</i> , 2016 , 43, 154-160	5.5	20
315	Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. <i>Journal of Clinical Oncology</i> , 2016 , 34, 542-9	2.2	242
314	A prospective analysis of surgery and survival in stage IV breast cancer (TBCRC 013).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1006-1006	2.2	29
313	Pilot trial of an implantable microdevice for In Vivo drug sensitivity testing in patients with early stage, triple negative breast cancer receiving neoadjuvant therapy.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS1101-TPS1101	2.2	0
312	Phase I/II trial of palbociclib in combination with bicalutamide for the treatment of androgen receptor (AR)+ metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS1103-TPS1103 ^{2,2}	2.2	4
311	Academic and Community Cancer Research United (ACCRU) RU011301I: Adjuvant ado-trastuzumab emtansine (T-DM1) for older patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS629-TPS629	2.2	
310	Accrual of older patients (pts) with breast cancer to Alliance systemic therapy trials over time: A151527.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1024-1024	2.2	1
309	Phase II study of gemcitabine (G), trastuzumab (H), and pertuzumab (P) for HER2-Positive metastatic breast cancer (MBC) after prior HP- or TDM/P-based therapy.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 611-611	2.2	
308	A genome-wide association study (GWAS) of progression-free survival (PFS) in metastatic breast cancer (MBC) patients treated with letrozole (L) with or without bevacizumab (B) in CALGB 40503.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 538-538	2.2	
307	Phase 1b/2 study of intratumoral Ad-RTS-hIL-12 + veledimex in patients with chemotherapy-responsive locally advanced or metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS3097-TPS3097	2.2	
306	Reply to L.A. Newman. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1015	2.2	
305	Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status. <i>Cancer</i> , 2016 , 122, 1178-84	6.4	29
304	Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016 , 14, 324-54	7.3	223

303	PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance). <i>Npj Breast Cancer</i> , 2016 , 2,	7.8	58
302	Obesity and Cancer Mechanisms: Tumor Microenvironment and Inflammation. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4270-4276	2.2	315
301	Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer. <i>Oncologist</i> , 2016 , 21, 418-24	5.7	37
300	Exocytosis of macrophage lysosomes leads to digestion of apoptotic adipocytes and foam cell formation. <i>Journal of Lipid Research</i> , 2016 , 57, 980-92	6.3	67
299	Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). <i>Journal of Clinical Oncology</i> , 2016 , 34, 2602-9	2.2	77
298	The epichaperome is an integrated chaperome network that facilitates tumour survival. <i>Nature</i> , 2016 , 538, 397-401	50.4	148
297	White adipose tissue inflammation and cancer-specific survival in patients with squamous cell carcinoma of the oral tongue. <i>Cancer</i> , 2016 , 122, 3794-3802	6.4	31
296	RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. <i>Journal of Clinical Oncology</i> , 2015 , 33, 709-15	2.2	239
295	American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2563-77	2.2	599
294	In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. <i>Mayo Clinic Proceedings</i> , 2015 , 90, 996-1000	6.4	105
293	Bilateral Mastectomy versus Breast-Conserving Surgery for Early-Stage Breast Cancer: The Role of Breast Reconstruction. <i>Plastic and Reconstructive Surgery</i> , 2015 , 135, 1518-1526	2.7	90
292	Obesity and Breast Cancer: Narrowing the Focus. <i>JAMA Oncology</i> , 2015 , 1, 622-3	13.4	1
291	Estrogen Protects against Obesity-Induced Mammary Gland Inflammation in Mice. <i>Cancer Prevention Research</i> , 2015 , 8, 751-9	3.2	21
290	Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance). <i>Journal of Clinical Oncology</i> , 2015 , 33, 2361-9	2.2	157
289	Appearance of untreated bone metastases from breast cancer on FDG PET/CT: importance of histologic subtype. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015 , 42, 1666-1673	8.8	50
288	Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial). <i>Breast Cancer Research and Treatment</i> , 2015 , 151, 589-96	4.4	46
287	Menopause is a determinant of breast adipose inflammation. <i>Cancer Prevention Research</i> , 2015 , 8, 349-58.2	5.2	69
286	Combination trastuzumab and chemotherapy may have a role in women with small, node-negative, human epidermal growth factor receptor 2-positive breast cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 124-5	2.2	2

285	Continuous Trastuzumab Therapy in Breast Cancer Patients With Asymptomatic Left Ventricular Dysfunction. <i>Oncologist</i> , 2015 , 20, 1105-10	5.7	23
284	Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance). <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	33
283	Neoadjuvant Therapy in Breast Cancer as a Basis for Drug Approval. <i>JAMA Oncology</i> , 2015 , 1, 875-6	13.4	37
282	Comparison of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma. <i>Journal of Nuclear Medicine</i> , 2015 , 56, 1674-80	8.9	52
281	Obesity-dependent changes in interstitial ECM mechanics promote breast tumorigenesis. <i>Science Translational Medicine</i> , 2015 , 7, 301ra130	17.5	175
280	Recommendations for Obesity Clinical Trials in Cancer Survivors: American Society of Clinical Oncology Statement. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3961-7	2.2	44
279	Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). <i>Journal of Clinical Oncology</i> , 2015 , 33, 13-21	2.2	590
278	Obesity and Cancer: Concepts and Challenges. <i>Indian Journal of Surgical Oncology</i> , 2015 , 6, 390-8	0.7	11
277	Big data: Are large prospective randomized trials obsolete in the future?. <i>Breast</i> , 2015 , 24 Suppl 2, S15-83.6		9
276	NCCN Guidelines Insights Breast Cancer, Version 1.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015 , 13, 1475-85	7.3	109
275	Breast Cancer Version 2.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015 , 13, 448-75	7.3	138
274	What Is the Optimum Timing of Postmastectomy Radiotherapy in Two-Stage Prosthetic Reconstruction: Radiation to the Tissue Expander or Permanent Implant?. <i>Plastic and Reconstructive Surgery</i> , 2015 , 135, 1509-1517	2.7	135
273	Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance). <i>Annals of Surgery</i> , 2015 , 262, 434-9; discussion 438-9	7.8	111
272	Reply to V. Amoroso et al. <i>Journal of Clinical Oncology</i> , 2015 , 33, 291	2.2	
271	Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. <i>New England Journal of Medicine</i> , 2015 , 372, 134-41	59.2	455
270	Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015 , 149, 489-95	4.4	44
269	Obesity and cancer: local and systemic mechanisms. <i>Annual Review of Medicine</i> , 2015 , 66, 297-309	17.4	166
268	The development of dose-dense adjuvant chemotherapy. <i>Breast Journal</i> , 2015 , 21, 42-51	1.2	7

267	Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 442-7	2.2	63
266	Abstract CT330: Phase I study of PI3K inhibitor BYL719 + aromatase inhibitor (AI) in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC) 2015 ,		3
265	Abstract P5-19-09: Preliminary results from a phase 2 single-arm study of enzalutamide, an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC) 2015 ,		7
264	Abstract S3-06: Mutational analysis of CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer 2015 ,		3
263	Abstract S4-05: Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) or bevacizumab (Bev): CALGB 40603/150709 (Alliance) 2015 ,		7
262	Abstract S6-05: Characterization of male breast cancer: First results of the EORTC10085/TBCRC/BIG/NABCG International Male BC Program 2015 ,		15
261	Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1003-1003	2.2	81
260	Impact of neoadjuvant therapy on breast conservation rates in triple-negative and HER2-positive breast cancer: Combined results of CALGB 40603 and 40601 (Alliance).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1007-1007	2.2	4
259	Standard chemotherapy versus capecitabine for older women with early stage breast cancer: An update of CALGB/CTSU/Alliance 49907.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1022-1022	2.2	3
258	Phase III trial evaluating the addition of bevacizumab to letrozole as first-line endocrine therapy for treatment of hormone-receptor positive advanced breast cancer: CALGB 40503 (Alliance).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 501-501	2.2	10
257	Phase I study of LJM716, BYL719, and trastuzumab in patients (pts) with HER2-amplified (HER2+) metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 590-590	2.2	15
256	Trastuzumab and pertuzumab-based versus other therapy as second-line therapy in HER2-positive metastatic breast cancer: A retrospective study from single center.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 616-616	2.2	1
255	Adjuvant hormonal therapy in premenopausal women with breast cancer. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2015 , 36, 195-200	0.2	3
254	Prevalence of hypomagnesemia in patients with HER2-positive breast cancer receiving pertuzumab treatment.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e11608-e11608	2.2	0
253	A combined screening approach of Fracture (Fx) Risk Algorithm (FRAX) and Trabecular Bone Score (TBS) to identify osteoporotic-range fracture risk (ORFR) in breast cancer (BC) patients treated with adjuvant aromatase inhibitor (AI).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 574-574	2.2	
252	A model-based approach to dose optimization of neurotoxic chemotherapy for metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1041-1041	2.2	
251	Ethnic disparities in the impact of breast cancer on the workforce: A pilot study.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e17600-e17600	2.2	
250	Oncotype DX in BRCA-associated vs. sporadic breast cancers: Differences based on germline mutation status and potential implications for adjuvant systemic therapy (AST).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 519-519	2.2	

249	Pilot study evaluating presence of crown-like structures in high grade endometrial carcinoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e16504-e16504	2.2	
248	Phase II study of weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer (MBC): Updated progression-free survival with overall survival result.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 607-607	2.2	
247	Characterization of dominant T-cell clones by T-cell receptor (TCR) deep sequencing as a potential predictive biomarker to neoadjuvant trastuzumab (tras) in HER2-positive (HER2+) breast cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 609-609	2.2	1
246	Cardiac safety of continuous trastuzumab therapy in breast cancer patients with asymptomatic left ventricular dysfunction.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e11602-e11602	2.2	
245	The role of LHRH agonists in ovarian function preservation in premenopausal women undergoing chemotherapy for early stage breast cancer: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1050-1050	2.2	
244	A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer. <i>Clinical Breast Cancer</i> , 2014 , 14, 154-60	3	75
243	Maastricht Delphi consensus on event definitions for classification of recurrence in breast cancer research. <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	60
242	Impact of obesity on the survival of patients with early-stage squamous cell carcinoma of the oral tongue. <i>Cancer</i> , 2014 , 120, 983-91	6.4	40
241	Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2255-69	2.2	545
240	Associations among survivorship care plans, experiences of survivorship care, and functioning in older breast cancer survivors: CALGB/Alliance 369901. <i>Journal of Cancer Survivorship</i> , 2014 , 8, 627-37	5.1	27
239	Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). <i>Journal of Clinical Oncology</i> , 2014 , 32, 2311-7	2.2	60
238	Breast cancer version 3.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014 , 12, 542-90	7.3	139
237	Web based pathology assessment in RTOG 98-04. <i>Journal of Clinical Pathology</i> , 2014 , 67, 777-80	3.9	5
236	American Society of Clinical Oncology position statement on obesity and cancer. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3568-74	2.2	322
235	Building a rapid learning health care system for oncology: the regulatory framework of CancerLinQ. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2373-9	2.2	79
234	Comorbidity, chemotherapy toxicity, and outcomes among older women receiving adjuvant chemotherapy for breast cancer on a clinical trial: CALGB 49907 and CALGB 361004 (alliance). <i>Journal of Oncology Practice</i> , 2014 , 10, e285-92	3.1	45
233	Diminishing relative contraindications for immediate breast reconstruction. <i>Plastic and Reconstructive Surgery</i> , 2014 , 134, 363e-369e	2.7	33
232	Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer: CALGB 40202 (Alliance). <i>Journal of Clinical Oncology</i> , 2014 , 32, 3959-66	2.2	66

231	Frailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2318-27	2.2	60
230	A pilot study of preoperative (Pre-op), single-dose ipilimumab (Ipi) and/or cryoablation (Cryo) in women (pts) with early-stage/resectable breast cancer (ESBC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1098-1098	2.2	8
229	CK14, FOXA1, and androgen receptor (AR) expression in patients (pts) with triple-negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1126-1126	2.2	1
228	Phase I trial of daily PI3K inhibitor BYL719 plus letrozole (L) or exemestane (E) for patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2605-2605	2.2	4
227	Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 506-506	2.2	11
226	Monitoring PIK3CA mutant allele fraction (AF) in cell-free DNA (cfDNA) in metastatic breast cancer (MBC) patients treated with PI3K inhibitor plus letrozole (L) or exemestane (E).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 517-517	2.2	1
225	Enzalutamide plus exemestane: A pilot study to assess safety, pharmacokinetics, and effects on circulating estrogens in women with advanced hormone-positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 545-545	2.2	1
224	A phase 2 single-arm study of the clinical activity and safety of enzalutamide in patients with advanced androgen receptor-positive triple-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS1144-TPS1144	2.2	1
223	A multicenter phase II study of docosahexaenoic acid (DHA) in patients (pts) with a history of breast cancer (BC), premalignant lesions, or benign breast disease.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS1615-TPS1615	2.2	1
222	Obesity and menopausal status as determinants of procarcinogenic breast inflammation.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 40-40	2.2	1
221	Tumor and systemic immune responses to preoperative (pre-op) cryoablation (cryo) plus immune therapy with ipilimumab (ipi) in early-stage breast cancer (ESBC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 64-64	2.2	1
220	Phase II feasibility study of paclitaxel (T) with trastuzumab (H) and lapatinib (L) for node-negative, HER2-positive breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 633-633	2.2	
219	T-cell receptor (TCR) DNA deep sequencing to evaluate clonality of tumor-infiltrating lymphocytes (TILs) in early-stage breast cancer patients (pts) receiving preoperative cryoablation (cryo) and/or ipilimumab (ipi).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3021-3021	2.2	0
218	Phase 2 feasibility study of dose-dense doxorubicin and cyclophosphamide (AC) followed by eribulin mesylate with or without prophylactic growth factor (GF) for adjuvant treatment of early-stage breast cancer (EBC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS670-TPS670	2.2	
217	A virtual consult service to optimize clinical trial participation in patients with metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 6601-6601	2.2	
216	A phase 3 trial comparing capecitabine in combination with Sorafenib or placebo for treatment of locally advanced or metastatic HER2-Negative breast Cancer (the RESILIENCE study): study protocol for a randomized controlled trial. <i>Trials</i> , 2013 , 14, 228	2.8	29
215	Omega-3 fatty acids for the prevention of breast cancer: an update and state of the science. <i>Current Breast Cancer Reports</i> , 2013 , 5, 247-254	0.8	18
214	Genetic deletion of microsomal prostaglandin E synthase-1 suppresses mouse mammary tumor growth and angiogenesis. <i>Prostaglandins and Other Lipid Mediators</i> , 2013 , 106, 99-105	3.7	20

213	ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. <i>Nature Genetics</i> , 2013 , 45, 1439-45	36.3	754
212	Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2382-7	2.2	695
211	Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2013 , 19, 5505-12	12.9	443
210	Dietary polyphenols suppress elevated levels of proinflammatory mediators and aromatase in the mammary gland of obese mice. <i>Cancer Prevention Research</i> , 2013 , 6, 886-97	3.2	32
209	Cognitive function in older women with breast cancer treated with standard chemotherapy and capecitabine on Cancer and Leukemia Group B 49907. <i>Breast Cancer Research and Treatment</i> , 2013 , 139, 607-16	4.4	21
208	A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013 , 139, 107-13	4.4	49
207	A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors. <i>Breast Cancer Research</i> , 2013 , 15, R110	8.3	72
206	A planned, prospective comparison of short-term quality of life outcomes among older patients with breast cancer treated with standard chemotherapy in a randomized clinical trial vs. an observational study: CALGB #49907 and #369901. <i>Journal of Geriatric Oncology</i> , 2013 , 4, 353-61	3.6	10
205	Randomized phase II trial of weekly vs. every 2 weeks vs. every 3 weeks nanoparticle albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic breast cancer. <i>Clinical Breast Cancer</i> , 2013 , 13, 239-246.e1	3	25
204	Obesity and Inflammation: New Insights into Breast Cancer Development and Progression. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013 , 46-51	7.1	74
203	Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017. <i>Cancer</i> , 2013 , 119, 1776-83	6.4	132
202	PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013 , 138, 457-66	4.4	78
201	Molecular pathways: adipose inflammation as a mediator of obesity-associated cancer. <i>Clinical Cancer Research</i> , 2013 , 19, 6074-83	12.9	228
200	Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy. <i>Clinical Cancer Research</i> , 2013 , 19, 491-9	12.9	45
199	Reply to P.G. Tsoutsou et al, o. Kaidar-Person et al, and A. Courdi et al. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4571-3	2.2	2
198	Pilot study of 68Ga-DOTA-F(ab)2-trastuzumab in patients with breast cancer. <i>Nuclear Medicine Communications</i> , 2013 , 34, 1157-65	1.6	48
197	Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab. <i>Clinical Cancer Research</i> , 2013 , 19, 2745-54	12.9	60
196	ASCOG approach to a learning health care system in oncology. <i>Journal of Oncology Practice</i> , 2013 , 9, 145-8	3.1	39

195	Caloric restriction reverses obesity-induced mammary gland inflammation in mice. <i>Cancer Prevention Research</i> , 2013 , 6, 282-9	3.2	47
194	Electrophysiological features of taxane-induced polyneuropathy in patients with breast cancer. <i>Journal of Clinical Neurophysiology</i> , 2013 , 30, 199-203	2.2	19
193	Acupuncture in the treatment of upper-limb lymphedema: results of a pilot study. <i>Cancer</i> , 2013 , 119, 2455-61	6.4	52
192	Prognostic value of quantitative fluorodeoxyglucose measurements in newly diagnosed metastatic breast cancer. <i>Cancer Medicine</i> , 2013 , 2, 725-33	4.8	40
191	Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer. <i>Cancer</i> , 2013 , 119, 1344-8	6.4	37
190	Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer. <i>Cancer</i> , 2013 , 119, 3943-51	6.4	16
189	Increased levels of urinary PGE-M, a biomarker of inflammation, occur in association with obesity, aging, and lung metastases in patients with breast cancer. <i>Cancer Prevention Research</i> , 2013 , 6, 428-36	3.2	60
188	Time to adjuvant chemotherapy for breast cancer in National Comprehensive Cancer Network institutions. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 104-12	9.7	79
187	Feasibility of long-term patient self-reporting of toxicities from home via the Internet during routine chemotherapy. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2580-5	2.2	100
186	Breast cancer, version 3.2013: featured updates to the NCCN guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013 , 11, 753-60; quiz 761	7.3	111
185	Obesity and inflammation: new insights into breast cancer development and progression. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013 , 46-51	7.1	89
184	Radiation therapy for breast cancer (BC) with central nervous system (CNS) metastases: A contemporary experience at Memorial Sloan-Kettering Cancer Center (MSKCC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 144-144	2.2	1
183	Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 167-167	2.2	
182	A pilot study of preoperative (Pre-op), single-dose ipilimumab (Ipi) and/or cryoablation (Cryo) in women (pts) with early-stage/resectable breast cancer (ESBC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 67-67	2.2	1
181	Lessons learned from the development of the CancerLinQ prototype: Clinical decision support.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 237-237	2.2	
180	Return to work in low-income Latina and non-Latina white breast cancer survivors: a 3-year longitudinal study. <i>Cancer</i> , 2012 , 118, 1664-74	6.4	60
179	Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012 , 131, 111-6	4.4	17
178	The role of targeted therapy and biomarkers in breast cancer treatment. <i>Clinical and Experimental Metastasis</i> , 2012 , 29, 807-19	4.7	30

177	Standardized uptake value by positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer. <i>Cancer</i> , 2012 , 118, 5454-62	6.4	48
176	A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints. <i>Lancet Oncology</i> , 2012 , 13, e240-8	21.7	51
175	Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer. <i>Clinical Cancer Research</i> , 2012 , 18, 6784-91	12.9	138
174	Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2218-26	2.2	108
173	Limited overall survival in patients with brain metastases from triple negative breast cancer. <i>Breast Journal</i> , 2012 , 18, 345-50	1.2	24
172	Serum N-telopeptide and bone-specific alkaline phosphatase levels in patients with osteonecrosis of the jaw receiving bisphosphonates for bone metastases. <i>Journal of Oral and Maxillofacial Surgery</i> , 2012 , 70, 2768-75	1.8	12
171	Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. <i>Cancer Discovery</i> , 2012 , 2, 356-65	24.4	211
170	A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumors. <i>Clinical Cancer Research</i> , 2012 , 18, 5090-8	12.9	51
169	Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer. <i>Cancer</i> , 2012 , 118, 1982-8	6.4	67
168	Radiation field design and regional control in sentinel lymph node-positive breast cancer patients with omission of axillary dissection. <i>Cancer</i> , 2012 , 118, 1994-2003	6.4	21
167	Long-term outcomes in breast cancer patients undergoing immediate 2-stage expander/implant reconstruction and postmastectomy radiation. <i>Cancer</i> , 2012 , 118, 2552-9	6.4	102
166	Current or recent pregnancy is associated with adverse pathologic features but not impaired survival in early breast cancer. <i>Cancer</i> , 2012 , 118, 3254-9	6.4	67
165	Favorable prognosis in patients with T1a/T1bN0 triple-negative breast cancers treated with multimodality therapy. <i>Cancer</i> , 2012 , 118, 4944-52	6.4	49
164	Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). <i>Breast Cancer Research and Treatment</i> , 2012 , 132, 1049-62	4.4	252
163	A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012 , 134, 13-20	4.4	41
162	Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer. <i>Cancer Prevention Research</i> , 2012 , 5, 1144-54	3.2	70
161	Reply to S. Mahesh. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4446-4446	2.2	
160	A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. <i>Clinical Cancer Research</i> , 2012 , 18, 5099-109	12.9	155

159	Can we really use retrospective subset analyses and surveillance, epidemiology, and end results data to drive clinical practice?. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3148-9; author reply 3149-50	2.2	4
158	Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4071-6	2.2	69
157	Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines?. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2179-82	2.2	35
156	Pioglitazone, a PPAR α agonist, suppresses CYP19 transcription: evidence for involvement of 15-hydroxyprostaglandin dehydrogenase and BRCA1. <i>Cancer Prevention Research</i> , 2012 , 5, 1183-94	3.2	25
155	CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, CRA1002-CRA1002	2.2	29
154	Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 134-134	2.2	2
153	Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012 , 10, 821-9	7.3	79
152	Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. <i>Cancer Prevention Research</i> , 2011 , 4, 1021-9	3.2	338
151	Invasive breast cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011 , 9, 136-222	7.3	99
150	Bone scans, bisphosphonates, and a lack of acute changes within the mandible. <i>Journal of Oral and Maxillofacial Surgery</i> , 2011 , 69, 114-9	1.8	8
149	Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer. <i>Clinical Breast Cancer</i> , 2011 , 11, 306-11	3	102
148	Anthracyclines and trastuzumab; getting to the heart of the matter: when getting to the heart is the matter. <i>Breast Cancer Research and Treatment</i> , 2011 , 127, 585-6	4.4	
147	Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer. <i>Cancer</i> , 2011 , 117, 4125-31	6.4	13
146	Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer. <i>Cancer</i> , 2011 , 117, 5461-8	6.4	66
145	Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. <i>Cancer Prevention Research</i> , 2011 , 4, 329-46	3.2	296
144	A safety and efficacy pilot study of acupuncture for the treatment of chronic lymphoedema. <i>Acupuncture in Medicine</i> , 2011 , 29, 170-2	1.9	33
143	p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905). <i>Clinical Cancer Research</i> , 2011 , 17, 5170-8	12.9	28
142	A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer. <i>Clinical Cancer Research</i> , 2011 , 17, 3398-407	12.9	28

141	Quality of life of older patients with early-stage breast cancer receiving adjuvant chemotherapy: a companion study to cancer and leukemia group B 49907. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1022-8	2.2	47
140	MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer. <i>Genes and Development</i> , 2011 , 25, 226-31	12.6	170
139	Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib. <i>Clinical Cancer Research</i> , 2011 , 17, 3490-9	12.9	109
138	HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. <i>Clinical Cancer Research</i> , 2011 , 17, 5132-9	12.9	330
137	Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 3761-6	11.5	241
136	Triple-negative breast cancer: an unmet medical need. <i>Oncologist</i> , 2011 , 16 Suppl 1, 1-11	5.7	542
135	The prostaglandin transporter regulates adipogenesis and aromatase transcription. <i>Cancer Prevention Research</i> , 2011 , 4, 194-206	3.2	14
134	American Society of Clinical Oncology endorsement of the cancer care Ontario practice guideline on adjuvant ovarian ablation in the treatment of premenopausal women with early-stage invasive breast cancer. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3939-42	2.2	47
133	Integrated positron emission tomography/computed tomography may render bone scintigraphy unnecessary to investigate suspected metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3154-9	2.2	98
132	Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2418-22	2.2	92
131	Cystoid macular edema secondary to nab-paclitaxel therapy. <i>Journal of Clinical Oncology</i> , 2010 , 28, e684-72		29
130	Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis. <i>Oncologist</i> , 2010 , 15, 1164-8	5.7	133
129	Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 628-33	2.2	41
128	Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2982-8	2.2	35
127	Breast cancer adjuvant chemotherapy decisions in older women: the role of patient preference and interactions with physicians. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3146-53	2.2	67
126	Trastuzumab-related cardiotoxicity following anthracycline-based adjuvant chemotherapy: how worried should we be?. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3407-10	2.2	40
125	American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3784-96	2.2	565
124	Intravenous bisphosphonate therapy does not acutely alter nuclear bone scan results. <i>Clinical Breast Cancer</i> , 2010 , 10, 33-9	3	6

123	Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer. <i>Clinical Breast Cancer</i> , 2010 , 10, 281-7	3	75
122	Postmastectomy intensity modulated radiation therapy following immediate expander-implant reconstruction. <i>Radiotherapy and Oncology</i> , 2010 , 94, 319-23	5.3	42
121	Dose-dense chemotherapy for breast cancer: what does the future hold?. <i>Future Oncology</i> , 2010 , 6, 951-65	6.5	7
120	Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. <i>Lancet Oncology</i> , 2010 , 11, 55-65	21.7	1065
119	Breast cancer: noninvasive and special situations. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010 , 8, 1182-207	7.3	6
118	Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer. <i>Clinical Breast Cancer</i> , 2010 , 10, 440-4	4	6
117	Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy: evaluating the effect of race/ethnicity. <i>Cancer</i> , 2010 , 116, 4168-77	6.4	32
116	Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction. <i>Journal of Clinical Oncology</i> , 2009 , 27, 6117-23	2.2	21
115	The 6q22.33 locus and breast cancer susceptibility. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009 , 18, 2468-75	4	22
114	Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3430-6	2.2	41
113	Trastuzumab: a picky partner?. <i>Clinical Cancer Research</i> , 2009 , 15, 6311-3	12.9	3
112	Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. <i>Clinical Cancer Research</i> , 2009 , 15, 2472-8	12.9	169
111	cDNA analysis demonstrates that the BRCA2 intronic variant IVS4-12del5 is a deleterious mutation. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2009 , 663, 84-9	3.3	8
110	Phase I study of nonpegylated liposomal doxorubicin plus trastuzumab in patients with HER2-positive breast cancer. <i>Clinical Breast Cancer</i> , 2009 , 9, 101-7	3	16
109	Latent bone metastasis in breast cancer tied to Src-dependent survival signals. <i>Cancer Cell</i> , 2009 , 16, 67-78	24.3	534
108	A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma. <i>Breast Cancer Research and Treatment</i> , 2009 , 115, 609-12	4.4	11
107	The role of adjuvant anthracyclines for breast cancer treatment: Can we use molecular predictors?. <i>Current Breast Cancer Reports</i> , 2009 , 1, 5-11	0.8	
106	Therapeutic options for metastatic breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2009 , 10, 967-81	4	47

105	Adjuvant chemotherapy in older women with early-stage breast cancer. <i>New England Journal of Medicine</i> , 2009 , 360, 2055-65	59.2	417
104	Malignant lesion segmentation in contrast-enhanced breast MR images based on the marker-controlled watershed. <i>Medical Physics</i> , 2009 , 36, 4359-69	4.4	37
103	Insight into barriers against optimal adherence to oral hormonal therapy in women with breast cancer. <i>Clinical Breast Cancer</i> , 2008 , 8, 155-61	3	61
102	Prolonged dose-dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasible. <i>Clinical Breast Cancer</i> , 2008 , 8, 418-24	3	8
101	Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel. <i>Cancer Treatment Reviews</i> , 2008 , 34, 223-30	14.4	10
100	Cyclooxygenase-2-derived prostaglandin E2 stimulates Id-1 transcription. <i>Journal of Biological Chemistry</i> , 2008 , 283, 33955-68	5.4	24
99	Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1331-7	2.2	465
98	EP2 and EP4 receptors regulate aromatase expression in human adipocytes and breast cancer cells. Evidence of a BRCA1 and p300 exchange. <i>Journal of Biological Chemistry</i> , 2008 , 283, 3433-3444	5.4	78
97	Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1642-9	2.2	481
96	Dose-dense chemotherapy with trastuzumab is an appropriate option. <i>Journal of Clinical Oncology</i> , 2008 , 26, 3655-6; author reply 3656	2.2	2
95	Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B. <i>Journal of Clinical Oncology</i> , 2008 , 26, 2659-65	2.2	24
94	Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1797-802	2.2	58
93	The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1216-22	2.2	51
92	Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-up. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1803-9	2.2	127
91	A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer. <i>Clinical Cancer Research</i> , 2008 , 14, 7878-83	12.9	95
90	Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1231-8	2.2	424
89	Mastectomy with immediate expander-implant reconstruction, adjuvant chemotherapy, and radiation for stage II-III breast cancer: treatment intervals and clinical outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008 , 70, 43-50	4	44
88	Adjuvant chemotherapy for early-stage breast cancer. <i>Hematology/Oncology Clinics of North America</i> , 2007 , 21, 207-22	3.1	1

87	Trastuzumab--mechanism of action and use in clinical practice. <i>New England Journal of Medicine</i> , 2007 , 357, 39-51	59.2	1790
86	Adjuvant treatment recommendations in older women with breast cancer: a survey of oncologists. <i>Critical Reviews in Oncology/Hematology</i> , 2007 , 61, 255-60	7	27
85	Dose-dense therapy in the treatment of early-stage breast cancer: an overview of the data. <i>Clinical Breast Cancer</i> , 2007 , 8 Suppl 1, S6-S10	3	12
84	Current status of the taxanes as adjuvant therapy for breast cancer. <i>Breast</i> , 2007 , 16 Suppl 2, S132-5	3.6	1
83	A case series of androgen use in breast cancer survivors with sexual dysfunction. <i>Journal of Sexual Medicine</i> , 2007 , 4, 1769-74	1.1	15
82	Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21. <i>Clinical Cancer Research</i> , 2007 , 13, 2977-85	12.9	73
81	Randomized, controlled trial of acupuncture for the treatment of hot flashes in breast cancer patients. <i>Journal of Clinical Oncology</i> , 2007 , 25, 5584-90	2.2	147
80	Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3699-704	2.2	226
79	HER2 and response to paclitaxel in node-positive breast cancer. <i>New England Journal of Medicine</i> , 2007 , 357, 1496-506	59.2	462
78	Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. <i>Journal of Clinical Oncology</i> , 2007 , 25, 2127-32	2.2	566
77	Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. <i>Journal of Clinical Oncology</i> , 2007 , 25, 5410-7	2.2	288
76	BRCA mutations in women with ductal carcinoma in situ. <i>Clinical Cancer Research</i> , 2007 , 13, 4306-10	12.9	26
75	Preoperative chemotherapy for breast cancer: miracle or mirage?. <i>JAMA - Journal of the American Medical Association</i> , 2007 , 298, 2665-7	27.4	11
74	Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623. <i>Journal of Clinical Oncology</i> , 2007 , 25, 1677-82	2.2	43
73	Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer. <i>Clinical Cancer Research</i> , 2007 , 13, 223-7	12.9	10
72	Breast cancer chemotherapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2007 , 13, 141-7	2.2	13
71	Pharmacokinetics and toxicity of weekly docetaxel in older patients. <i>Clinical Cancer Research</i> , 2006 , 12, 6100-5	12.9	65
70	Trastuzumab adds to adjuvant chemotherapy for resected HER2-positive breast cancer. <i>Nature Clinical Practice Oncology</i> , 2006 , 3, 12-3		3

69	Can granulocyte-colony stimulating factor worsen anemia?. <i>Journal of Clinical Oncology</i> , 2006 , 24, 2985-6.2		2
68	Cancer and leukemia group B breast committee: decades of progress and plans for the future. <i>Clinical Cancer Research</i> , 2006 , 12, 3576s-80s	12.9	2
67	Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. <i>JAMA - Journal of the American Medical Association</i> , 2006 , 295, 1658-67	27.4	549
66	HER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanism. <i>Cancer Research</i> , 2006 , 66, 5504-11	10.1	80
65	Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women@ Intervention Nutrition Study. <i>Journal of the National Cancer Institute</i> , 2006 , 98, 1767-76	9.7	633
64	CALGB 9344/CALGB C9741: What have we learned?. <i>European Journal of Cancer, Supplement</i> , 2006 , 4, 10-12	1.6	1
63	Inadvertent use of aromatase inhibitors in patients with breast cancer with residual ovarian function: cases and lessons. <i>Clinical Breast Cancer</i> , 2006 , 7, 158-61	3	24
62	A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer. <i>Clinical Breast Cancer</i> , 2006 , 7, 270-7	3	76
61	Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study. <i>Journal of the American Geriatrics Society</i> , 2006 , 54, 925-31	5.6	198
60	A prospective, longitudinal study of the functional status and quality of life of older patients with breast cancer receiving adjuvant chemotherapy. <i>Journal of the American Geriatrics Society</i> , 2006 , 54, 1119-24	5.6	76
59	Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient@ perspective. <i>Breast Cancer Research and Treatment</i> , 2006 , 98, 343-8	4.4	71
58	Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806. <i>Breast Cancer Research and Treatment</i> , 2006 , 100, 301-8	4.4	20
57	Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer. <i>Cancer Investigation</i> , 2005 , 23, 483-7	2.1	32
56	American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. <i>Journal of Clinical Oncology</i> , 2005 , 23, 619-29	2.2	672
55	Weekly epoetin alfa during adjuvant chemotherapy for breast cancer: effect on hemoglobin levels and quality of life. <i>Clinical Breast Cancer</i> , 2005 , 6, 132-42	3	24
54	Effect of creatinine clearance on patterns of toxicity in older patients receiving adjuvant chemotherapy for breast cancer. <i>Drugs and Aging</i> , 2005 , 22, 785-91	4.7	22
53	Radiation pneumonitis in breast cancer patients treated with taxanes: does sequential radiation therapy lower the risk?. <i>Breast Journal</i> , 2005 , 11, 317-20	1.2	7
52	The best use of adjuvant chemotherapy: new drugs and new use of "old" drugs. <i>Breast</i> , 2005 , 14, 570-5	3.6	4

51	Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series. <i>Cancer</i> , 2005 , 103, 44-51	6.4	123
50	The effect of changes in tumor size on breast carcinoma survival in the U.S.: 1975-1999. <i>Cancer</i> , 2005 , 104, 1149-57	6.4	97
49	Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. <i>Cancer</i> , 2005 , 104, 1575-9	6.4	150
48	Developing a cancer-specific geriatric assessment: a feasibility study. <i>Cancer</i> , 2005 , 104, 1998-2005	6.4	435
47	A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2005 , 90, 157-63	4.4	76
46	Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2005 , 92, 151-6	4.4	40
45	HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice. <i>Cancer Research</i> , 2005 , 65, 10113-9	10.1	136
44	Testing chemotherapy for breast cancer: timing is everything. <i>Journal of Clinical Oncology</i> , 2005 , 23, 5434-6		8
43	Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. <i>JAMA - Journal of the American Medical Association</i> , 2005 , 293, 1073-81	27.4	318
42	Clinical implications of antiangiogenic therapies. <i>Oncology</i> , 2005 , 19, 26-31	1.8	14
41	Introduction: Examining the Potential Impact of Anemia Treatment on Clinical Outcomes in Anemic Cancer Patients. <i>Oncologist</i> , 2004 , 9, 1-3	5.7	1
40	Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer. <i>Clinical Cancer Research</i> , 2004 , 10, 5754-61	12.9	29
39	Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments. <i>Clinical Cancer Research</i> , 2004 , 10, 4062-7	12.9	59
38	Epoetin alfa: future directions and future research. <i>Oncologist</i> , 2004 , 9 Suppl 5, 70-3	5.7	1
37	Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. <i>New England Journal of Medicine</i> , 2004 , 351, 971-7	59.2	766
36	Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. <i>Journal of Clinical Oncology</i> , 2004 , 22, 2061-8	2.2	230
35	HER-2 Testing in Breast Cancer Using Immunohistochemical Analysis and Fluorescence In Situ Hybridization. <i>American Journal of Clinical Pathology</i> , 2004 , 121, 631-636	1.9	130
34	rHuEPO and treatment outcomes: the clinical experience. <i>Oncologist</i> , 2004 , 9 Suppl 5, 55-69	5.7	20

33	Dose-dense chemotherapy in breast cancer and lymphoma. <i>Seminars in Oncology</i> , 2004 , 31, 19-26	5.5	24
32	Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin?. <i>Cancer</i> , 2004 , 100, 2052-63	6.4	102
31	Cytokeratin-positive cells in sentinel lymph nodes in breast cancer are not random events: experience in patients undergoing prophylactic mastectomy. <i>Cancer</i> , 2004 , 101, 926-33	6.4	47
30	A tool for predicting breast carcinoma mortality in women who do not receive adjuvant therapy. <i>Cancer</i> , 2004 , 101, 2509-15	6.4	39
29	A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. <i>Breast Cancer Research</i> , 2004 , 6, R8-R17	8.3	225
28	American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting. <i>Journal of Clinical Oncology</i> , 2003 , 21, 2597-9	2.2	70
27	Expedition Inspiration Fund for Breast Cancer Research Meeting 2003. <i>Breast Cancer Research and Treatment</i> , 2003 , 80, 139-44	4.4	
26	Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations. <i>Cancer</i> , 2003 , 97, 1601-8	6.4	79
25	Factors influencing treatment patterns of breast cancer patients age 75 and older. <i>Critical Reviews in Oncology/Hematology</i> , 2003 , 46, 121-6	7	112
24	Follow-up care of breast cancer survivors. <i>Critical Reviews in Oncology/Hematology</i> , 2003 , 48, 89-99	7	15
23	Current status and future directions in breast cancer therapy. <i>Clinical Breast Cancer</i> , 2003 , 4 Suppl 2, S70-5	3	25
22	The use of taxanes in early breast cancer. <i>European Journal of Cancer, Supplement</i> , 2003 , 1, 1-10	1.6	5
21	Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2002 , 20, 2319-26	2.2	69
20	American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. <i>Journal of Clinical Oncology</i> , 2002 , 20, 3317-27	2.2	196
19	Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2002 , 20, 3665-73	2.2	26
18	Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. <i>New England Journal of Medicine</i> , 2002 , 346, 1609-15	59.2	1198
17	Single-agent vs combination therapy in advanced breast cancer: potential roles of capecitabine. <i>Oncology</i> , 2002 , 16, 13-6	1.8	17
16	Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2001 , 19, 1539-69	2.2	659

15	Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a phase I/II clinical trial. <i>Breast Cancer Research and Treatment</i> , 2001 , 66, 239-48	4.4	163
14	Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. <i>Journal of Clinical Oncology</i> , 2001 , 19, 2587-95	2.2	474
13	A pilot study of interpersonal psychotherapy by telephone with cancer patients and their partners. <i>Psycho-Oncology</i> , 2000 , 9, 44-56	3.9	87
12	An immunotherapeutic approach to treatment of breast cancer: focus on trastuzumab plus paclitaxel. Breast Cancer Medicine Service. <i>Cancer Chemotherapy and Pharmacology</i> , 2000 , 46 Suppl, S23-35	3.5	4
11	Role of taxanes in adjuvant therapy. <i>Cancer Investigation</i> , 2000 , 18, 32-8	2.1	4
10	A pilot study of Interpersonal Psychotherapy by telephone with cancer patients and their partners 2000 , 9, 44		8
9	Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. <i>Journal of the National Cancer Institute</i> , 1999 , 91, 2112-7	9.7	149
8	Adjuvant therapy for resectable breast cancer. <i>Hematology/Oncology Clinics of North America</i> , 1999 , 13, 391-413, vi	3.1	6
7	Lack of increased cardiac toxicity with sequential doxorubicin and paclitaxel. <i>Cancer Investigation</i> , 1998 , 16, 67-71	2.1	9
6	Paclitaxel-induced pancreatitis: a case report. <i>Journal of the National Cancer Institute</i> , 1997 , 89, 91-3	9.7	15
5	Is there an alternative to alternating adjuvant therapy for breast cancer?. <i>Cancer Investigation</i> , 1994 , 12, 329-35	2.1	1
4	Do we need a "stopping rule" for breast cancer?. <i>Cancer Investigation</i> , 1994 , 12, 543-4	2.1	
3	Taxol and recombinant human granulocyte colony-stimulating factor, an active regimen as initial therapy for metastatic breast cancer. A preliminary report. <i>Annals of the New York Academy of Sciences</i> , 1993 , 698, 398-402	6.5	1
2	Phase II trial of carboplatin and etoposide in metastatic breast cancer. <i>Cancer</i> , 1993 , 71, 1254-7	6.4	12
1	A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma. <i>Cancer</i> , 1991 , 68, 965-9	6.4	70